The endpoints of all-cause death, myocardial infarction, stent thrombosis, and stroke did not differ between P2Y12 inhibitor monotherapy and conventional DAPT in both complex PCI and non-complex PCI patient groups. This evidence concerns the gene P2RY12 and Stroke.